Skip to main content
LUCD logo

LUCD · Lucid Diagnostics Inc.

Track LUCD — free
$0.43 -0.02 (-4.83%)
Market Cap
$92.95M
Shares
206.98M
Volume · Nov 16 1.14M Avg daily vol (3M) 4.99M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.45 Open$0.44 Day$0.42–0.49 52W close$0.33–1.47 Avg vol 30d9.4M Short int15.0M · 7.2% of shares · 1.0d Short vol46% Last earningsNov 12, 2026 DataOct 2021–Nov 2026 Filing10-Q · Nov 12

Up next

Mar 25, 2027 Est · unconfirmed · in 18 wks

Latest documents

2026
Nov 12
Earnings call
Medicare reimbursement unlocks commercial acceleration

Medicare now pays for Lucid Diagnostics’ ESAGard test, enabling commercial acceleration. Third-quarter revenue was $1.2 million from 2,871 tests, while October volume exceeded 1,800 and pro forma cash reached approximately $33 million.

4 source passages
For the first time, Medicare beneficiaries nationwide have fully reimbursed access to our groundbreaking ESAGard test. Our sales team sold 2,871 tests in the third quarter with a billable value of approximately $7.9 million. Resulting in recognized revenue of $1.2 million. October test volume for all patients, both Medicare and non-Medicare, achieved a record monthly level for the company at more than 1,800 tests in just the first month of the fourth quarter. subsequent to quarter end on October 21st, we closed a $15 million Series C convertible preferred offering, which brings our pro forma cash position to approximately $33 million. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going concern raised despite $15.0 million Series C raise

Lucid Diagnostics Inc. reported a $45.0 million net loss attributable to common stockholders for nine months ended September 30, 2026, raising substantial doubt about continuing as a going concern. A subsequent Series C preferred stock sale raised approximately $15.0 million.

Revenue $1.2M ▼ 0.7% Net loss $6.68M
Read from the first part of this long document
4 source passages
Lucid Diagnostics Inc. (“Lucid”, “Lucid Diagnostics”, or the “Company”) is a commercial-stage, cancer prevention medical diagnostics company. The Company incurred a net loss attributable to its common stockholders of approximately $45.0 million and had net cash flows used in operating activities of approximately $38.9 million for the nine months ended September 30, 2026. Subsequent to September 30, 2026, on October 21, 2026, the Company entered into subscription agreements for, and closed on, the sale of 15,000 shares of Series C Convertible Preferred Stock, for aggregate gross proceeds to the Company of approximately $15.0 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued. Open the document at this passage
Nov 12
Current report 8-K
EsoGuard fully reimbursed nationwide by Medicare

Lucid Diagnostics Inc. said EsoGuard is now fully reimbursed nationwide by Medicare, received its first Medicare payments in October at $1,938.01 per test, and recorded $1.2 million in third-quarter revenue.

Financial results, Regulation FD disclosure
3 source passages
Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test Lucid has consistently received payments on these claims at EsoGuard’s established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. For the three months ended September 30, 2026, EsoGuard related revenues were $1.2 million. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 12
Delisting notice or listing transfer

Lucid Diagnostics Inc. received a Nasdaq notice on October 12, 2026 that its common stock traded below the $1 minimum bid price for 30 consecutive business days, giving it until April 12, 2027 to regain compliance.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.44M
Trailing 12 months
Net income (TTM)
−$48.54M
Trailing 12 months
Revenue growth YoY
-0.7%
Year over year
Operating margin
-941.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-55.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+114.7%
Year over year · more shares
Price change (1Y)
-58.0%
Trailing year
Short interest
7.2%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Medicare reimbursement, record October test volume, new financing, and expanding commercial and VA coverage mark a positive commercial acceleration. However, third-quarter revenue declined sequentially from $1.5 million to $1.2 million, the company reported a $6.7 million GAAP net loss, the Series C carries a 20% stock-paid dividend with approximately 330 million fully diluted shares, and the draft MolDX LCD remains unpublished amid an administrative backlog.

Bullish
  • + Medicare payments for EsoGuard began in October at $1,938.01 per test, with every allowed claim paid at the full rate.
  • + October test volume reached a record monthly level of more than 1,800 tests.
  • + A $15 million financing gave management confidence that the company has sufficient runway for commercial acceleration and revenue growth.
  • + Quarterly cash burn was $10.2 million, the lowest of the last four quarters.
  • + Five Concert client health plans are expected to adopt the EsoGuard coverage policy by year-end.
  • + Lucid launched its first two VA programs and expects VA to become a meaningful long-term contributor.
Bearish
  • − Third-quarter revenue was $1.2 million, essentially flat year over year and down from $1.5 million in the second quarter.
  • − The company reported a $6.7 million GAAP net loss attributable to common stockholders in the third quarter.
  • − Cash and cash equivalents were $18.0 million at September 30, 2026, compared to $34.7 million at December 31, 2025.
  • − The Series C preferred carries a 20% annual stock-paid dividend, and fully diluted shares are approximately 330 million.
  • − The pending draft MolDX LCD remains unpublished amid a persistent administrative backlog.
  • − Only 39% of adjudicated third-quarter claims resulted in an allowable amount from the insurance company.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −25%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 11%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −60%
trailing
YTD return −59%
this year
Relative strength −60%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
98 of 116 funds reported for Sep 30 · net -1.6M sh shares · +8 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.24% of shares out · ▲ +10.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
116 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth +79%
Y/Y
Gross margin 9%
contracting
EPS growth +17%
Y/Y
Free cash flow $-46.7M
Balance sheet $10.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −78%
past year
ATR 13.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 13, 2026
Test · for the next patient to endure $2,000
Margin · for the next patient to endure 90%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
11% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
98 of 116 funds reported for Sep 30 · net -1.6M sh shares · +8 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.24% of shares out · ▲ +10.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
116 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 11% Range high $1
vs 200-day avg -54% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Clinical Laboratory Fee Schedule rate $1,938.01 October —
EsoGuard test volume 1,800 October —
EsoGuard tests 2,871 3Q26 —
Non-GAAP adjusted (loss) income per share non-GAAP -$0.06 the three months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LUCD
Lucid Diagnostics Inc.
this stock
$92.95M -58.8% +79.0% — 7.2%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
108
% held
28.9%
Reported
98 of 116
Top holder
Alyeska Investment Group,…
Held Float
View
Held by Funds
Fund positions
70
View
Short & Settlement
Short Interest Rising
Shares short
15.0M
Days to cover
1.0d
Change
+1.4M sh
View
Short Volume
Short vol %
46%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
6.6K
Value
$2.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
68.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.3M
Net income (FY)
$-58.0M
EPS diluted
$-1.05
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
21

Lucid Diagnostics Inc. reported a $45.0 million net loss attributable to common stockholders for nine months ended September 30, 2026, raising substantial doubt about continuing as a going concern. A subsequent Series C preferred stock sale raised approximately $15.0 million.

View
Proposed Sales
Value
$49.1K
Shares
33.9K
Filed
Sep 26, 2023
View
Exempt Offerings
Offering
$22.0M
Filed
Dec 6, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Lucid Diagnostics Provides Busine…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
LUCD +12.8% -6.1% -59.5% +10.9% -58.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +10.3% -4.9% -60.0% +11.1% -69.4%
Key facts CIK 1799011 CUSIP 54948X109 13F (30d) 77 filings 73 filers Visit website Investor relations